Synedica Glow Skin 112mg

Synedica Glow Skin 112mg

Synedica Glow Skin 112mg is a research-focused multi-peptide formulation combining GHK-Cu, BPC-157 and TB-500 in an injection pen format. The current Synedica product listing identifies Glow Skin 112mg within its cosmetic research range, with a total formulation content of 112mg.

The listed formulation contains 80mg of GHK-Cu, 16mg of BPC-157 and 16mg of TB-500. These three peptides have different scientific backgrounds and have been investigated in areas including skin biology, extracellular-matrix research, cellular signalling and tissue biology.

Because the evidence for these compounds varies considerably by ingredient, study type and route of administration, research information should be distinguished from established clinical claims.

Synedica Glow Skin 112mg Product Overview

The Synedica Glow Skin 112mg formulation is presented as a multi-component peptide research product. According to the current product information, the formulation contains three listed peptide components with a combined total of 112mg.

Specification	Product Information
Product	Synedica Glow Skin 112mg
Formulation	GHK-Cu + BPC-157 + TB-500
Total formulation content	112mg
GHK-Cu	80mg
BPC-157	16mg
TB-500	16mg
Listed format	Injection Pen Kit
Listed dose format	40 × 2.8mg
Research category	Cosmetic / Peptide Research

Explore additional formulations through our Synedica research products collection.

What Is Synedica Glow Skin 112mg?

Synedica Glow Skin 112mg combines three compounds that have attracted interest across different areas of peptide and biological research: GHK-Cu, BPC-157 and TB-500.

GHK-Cu is a copper-binding tripeptide investigated in skin and extracellular-matrix biology. BPC-157 is a synthetic peptide studied primarily in experimental and preclinical research. TB-500 is associated with research into thymosin-beta-related cellular and tissue processes.

Combining these compounds into a single formulation does not automatically establish that research findings involving one ingredient apply to the complete combination. Formulation-specific research remains important when evaluating multi-peptide products.

GHK-Cu Research

GHK-Cu is one of the principal components of the Glow Skin formulation. It is a copper-complexed peptide that has been investigated in relation to skin biology, extracellular-matrix processes and collagen-related pathways.

Scientific literature has examined GHK and GHK-Cu in relation to skin appearance and biological processes. However, the available evidence is not sufficient to treat a research formulation as a clinically established anti-ageing or skin-repair treatment.

A recent evidence review notes that GHK-Cu research includes small controlled dermatological studies, while overall certainty remains limited. Researchers should therefore distinguish laboratory findings and small human studies from definitive clinical conclusions.

For additional scientific background, see the independent GHK-Cu evidence review.

BPC-157 Research

BPC-157 is the second listed peptide in the Synedica Glow Skin 112mg formulation. Research interest surrounding BPC-157 has focused primarily on experimental models involving tissue biology, cellular signalling and other biological processes.

The evidence base for BPC-157 remains predominantly preclinical. A systematic review published in 2025 found that the available literature was heavily weighted toward preclinical studies, with limited clinical evidence.

This means that findings from laboratory or animal models should not be presented as proof that a BPC-157-containing product produces a particular outcome in humans.

TB-500 Research

TB-500 is the third listed component of the Glow Skin formulation and is commonly discussed in relation to thymosin-beta research.

Research involving thymosin beta-4 has investigated cellular migration, tissue biology, vascular processes and wound-related pathways. However, it is important to distinguish research involving full-length thymosin beta-4 from research specifically involving TB-500.

A 2026 scoping review found that the literature surrounding thymosin beta-4 and TB-500 is uneven and predominantly preclinical, with direct evidence for TB-500 remaining limited.

Researchers can review the recent 2026 scoping review of thymosin beta-4 and TB-500 research.

Synedica Glow Skin 112mg Formulation

The three components of Synedica Glow Skin 112mg are listed as follows:

• GHK-Cu — 80mg: Copper-peptide research component associated with skin and extracellular-matrix research.
• BPC-157 — 16mg: Experimental peptide primarily investigated in preclinical research.
• TB-500 — 16mg: Peptide associated with thymosin-beta-related cellular and tissue research.

The listed combined formulation therefore contains a total of 112mg.

Why Composition Matters in Peptide Research

Researchers evaluating multi-component peptide formulations should consider the complete formulation rather than relying solely on evidence relating to individual ingredients.

Important considerations can include:

• Ingredient identity
• Individual component quantities
• Total formulation content
• Purity and analytical testing
• Product consistency
• Stability information
• Manufacturer documentation
• Batch identification
• Storage requirements
• Intended research application

Research concerning an individual peptide does not automatically establish the safety, efficacy or performance of a combination product containing several peptides.

Synedica Glow Skin 112mg Research Applications

The formulation may be relevant to research exploring different aspects of peptide and skin biology. GHK-Cu research includes extracellular-matrix and skin-related pathways, while BPC-157 and TB-500 have been investigated in experimental tissue and cellular models.

Potential research areas may therefore include:

• Skin biology research
• Extracellular-matrix research
• Peptide signalling research
• Cellular biology
• Collagen-related pathways
• Tissue biology research
• Experimental regenerative biology

These research areas should not be interpreted as approved indications or proof of clinical effectiveness for the combined formulation.

Quality & Product Documentation

When evaluating research peptides, appropriate product documentation is an important part of the research process. Researchers should consider identity, purity, batch information, formulation consistency and available analytical documentation.

Always review the current manufacturer documentation associated with the specific product and batch supplied. Product descriptions should not replace batch-specific analytical information.

For additional Synedica formulations, visit our Synedica product collection.

Research Evidence for Glow Skin Ingredients

The scientific evidence surrounding the individual ingredients is not uniform. GHK-Cu has been investigated in skin-related research, while BPC-157 research remains largely preclinical. Research concerning thymosin beta-4 provides biological context for some TB-500 discussions, but evidence for TB-500 itself remains much more limited.

A 2026 scoping review of thymosin beta-4 and TB-500 literature concluded that the evidence base is uneven and largely preclinical, with limited human evidence directly applicable to TB-500.

Similarly, an independent evidence review of GHK-Cu describes the available evidence as low certainty and notes that the compound does not have marketing authorisation for the uses evaluated in that review.

These limitations are important when creating accurate product information for Synedica Glow Skin 112mg.

Important Research Information

Synedica Glow Skin 112mg is presented as research material and is not intended for human or veterinary consumption. It should not be represented as an approved medicine, cosmetic treatment, anti-ageing treatment or cure for a medical condition.

Claims about skin rejuvenation, collagen production, wound healing, tissue repair or anti-ageing effects should not be presented as established clinical outcomes for this combined formulation.

The 112mg specification describes the listed total formulation content. It should not be interpreted as a recommended human dose or dosing schedule.

Storage & Handling

Storage and handling should follow the manufacturer’s current documentation supplied with the relevant product and batch. Researchers should consult the applicable product information for storage, stability and handling requirements.

Research materials should be handled according to appropriate laboratory procedures and applicable requirements. This product page does not provide human-use dosing instructions.

Frequently Asked Questions

What is Synedica Glow Skin 112mg?

Synedica Glow Skin 112mg is a multi-peptide research formulation containing GHK-Cu, BPC-157 and TB-500, with a listed total formulation content of 112mg.

What does Synedica Glow Skin 112mg contain?

The listed formulation contains 80mg of GHK-Cu, 16mg of BPC-157 and 16mg of TB-500.

What is the total amount in Glow Skin 112mg?

The listed total formulation content is 112mg, consisting of the three specified peptide components.

What is GHK-Cu?

GHK-Cu is a copper-complexed tripeptide that has been investigated in skin biology, extracellular-matrix research and related cellular processes.

What is BPC-157?

BPC-157 is a synthetic peptide that has primarily been investigated in experimental and preclinical research involving various biological pathways.

What is TB-500?

TB-500 is a peptide associated with research into cellular and tissue biology. Research specific to TB-500 remains considerably more limited than the broader literature on thymosin beta-4.

Is Synedica Glow Skin 112mg clinically proven for skin rejuvenation?

No. The available evidence concerning the individual ingredients and the combined formulation does not establish the product as a clinically proven skin-rejuvenation treatment.

Is Synedica Glow Skin 112mg a medicine?

No. It is presented as research material and should not be represented as an approved medicinal product.

Where can I find other Synedica products?

Visit the Synedica research products collection to explore other available Synedica formulations.

Is this product page medical advice?

No. This page provides general product and research information and is not medical advice, diagnosis or treat